论文部分内容阅读
目的观察晚期非小细胞肺癌(NSCLC)放化疗获益后采用参一胶囊维持治疗的临床效果。方法将60例NSCLC患者随机分为治疗组和对照组各30例。对照组给予放化疗治疗,后期仅接受定期随访观察。治疗组于放化疗后采用参一胶囊维持治疗,比较2组临床疗效、生活质量水平、免疫功能和不良反应。结果截止至2014年12月30日,期间无脱落病例。治疗组疾病控制率为53.3%(16/30)高于对照组的33.3%(10/30)(P<0.05)。治疗组患者Karnofsky评分升高例数多于对照组(P<0.05)。且治疗组患者出现肿瘤发展后患者接受了二线治疗11例(11/14,78.6%)高于对照组的10例(10/22,45.4%)(P<0.05)。治疗前2组免疫功能指标差异无统计学意义(P>0.05)。治疗后2组免疫功能指标均低于治疗前,但治疗组降低幅度低于对照组(P均<0.05)。结论晚期NSCLC放化疗后续采用参一胶囊维持治疗,可改善生活质量、提高免疫功能,有利于患者接受二线治疗,且安全性良好,值得进一步研究与推广。
Objective To observe the clinical effect of using Shen capsule in the treatment of advanced non-small cell lung cancer (NSCLC) after radiotherapy and chemotherapy. Methods Sixty NSCLC patients were randomly divided into treatment group and control group, 30 cases each. The control group was treated with radiotherapy and chemotherapy, and the latter only received regular follow-up observation. The patients in the treatment group were treated with “Shen Capsule” after radiotherapy and chemotherapy. The clinical efficacy, quality of life, immune function and adverse reactions in the two groups were compared. Results as of December 30, 2014, during the absence of cases of shedding. The disease control rate was 53.3% (16/30) in the treatment group and 33.3% (10/30) in the control group (P <0.05). Karnofsky score increased more in the treatment group than in the control group (P <0.05). In the treatment group, 11 patients (11/14, 78.6%) received the second-line therapy after the tumor developed, which was higher than that of the control group (10 / 22,45.4%) (P <0.05). There was no significant difference in immune function between the two groups before treatment (P> 0.05). After treatment, the immune function indexes of two groups were lower than those before treatment, but the reduction rate of the treatment group was lower than that of the control group (all P <0.05). Conclusions Chemotherapy and Chemotherapy for advanced NSCLC follow-up one capsule maintenance treatment can improve the quality of life, improve immune function, is conducive to patients receiving second-line treatment, and good safety, it is worth further study and promotion.